Universität zu Köln

Hoffmann, Thorben, Morcos, Yousef Ashraf Tawfik, Janoschek, Ruth ORCID: 0000-0002-1332-9353, Turnwald, Eva-Maria, Gerken, Antje, Mueller, Annette, Sengle, Gerhard, Doetsch, Joerg, Appel, Sarah ORCID: 0000-0003-0315-6513 and Hucklenbruch-Rother, Eva (2022). Correlation of metabolic characteristics with maternal, fetal and placental asprosin in human pregnancy. Endocr. Connect., 11 (3). BRISTOL: BIOSCIENTIFICA LTD. ISSN 2049-3614

Full text not available from this repository.

Abstract

ObjectiveAsprosin is a recently discovered hormone associated with obesity and diabetes mellitus. Little is known about asprosin's role during pregnancy, but a contribution of asprosin to pregnancy complications resulting from maternal obesity and gestational diabetes mellitus (GDM) is conceivable. We assessed the potential effects of obesity, GDM and other clinical parameters on maternal and fetal umbilical plasma asprosin concentrations and placental asprosin expression. DesignThe Cologne-Placenta Cohort Study comprises 247 female patients, from whom blood and placentas were collected at the University Hospital Cologne. MethodsWe studied the maternal and fetal umbilical plasma and placentas of pregnant women with an elective, primary section. Sandwich ELISA measurements of maternal and fetal umbilical plasma and immunohistochemical stainings of placental tissue were performed to determine the asprosin levels. Also, the relation between asprosin levels and clinical blood parameters was studied. ResultsThere was a strong correlation between the maternal and fetal plasma asprosin levels and both increased with GDM in normal-weight and obese women. Asprosin immunoreactivity was measured in cultivated placental cells and placental tissue. BMI and GDM were not but pre-pregnancy exercise and smoking were correlated with maternal and/or fetal asprosin levels. Placental asprosin levels were associated with maternal but not with fetal plasma asprosin levels and with BMI but not with GDM. Placental asprosin was related to maternal insulin levels and increased upon insulin treatment in GDM patients. ConclusionsAsprosin could potentially act as a biomarker and contribute to the clinical manifestation of pregnancy complications associated with maternal obesity.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoffmann, Thorben UNSPECIFIED UNSPECIFIED UNSPECIFIED Morcos, Yousef Ashraf Tawfik UNSPECIFIED UNSPECIFIED UNSPECIFIED Janoschek, Ruth UNSPECIFIED orcid.org/0000-0002-1332-9353 UNSPECIFIED Turnwald, Eva-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Gerken, Antje UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Annette UNSPECIFIED UNSPECIFIED UNSPECIFIED Sengle, Gerhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Doetsch, Joerg UNSPECIFIED UNSPECIFIED UNSPECIFIED Appel, Sarah UNSPECIFIED orcid.org/0000-0003-0315-6513 UNSPECIFIED Hucklenbruch-Rother, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-664720
DOI:	10.1530/EC-22-0069
Journal or Publication Title:	Endocr. Connect.
Volume:	11
Number:	3
Date:	2022
Publisher:	BIOSCIENTIFICA LTD
Place of Publication:	BRISTOL
ISSN:	2049-3614
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GESTATIONAL DIABETES-MELLITUS; PLASMA ASPROSIN; LEPTIN; INFLAMMATION; ADIPOKINES; NICOTINE; RESISTIN; PATHWAY; INSULIN; WEIGHT Multiple languages Endocrinology & Metabolism Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66472